Mayne Pharma presentation at JP Morgan Healthcare Conference
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA PRESENTATION AT THE 42ND ANNUAL J.P.
MORGAN HEALTHCARE CONFERENCE
11 January 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced
that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 42nd Annual
J.P. Morgan Healthcare Conference as follows:
Date:
Time:
Webcast:
Thursday, 11 January 2024
7:30am PST / 10:30 am EST (2.30am on Friday 12 January 2024 AEDT)
Click here
A copy of the presentation slides is attached.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
USA:
Lisa M. Wilson
+1 917-543-9932
ir@maynepharma.com
Authorised for release to the ASX by the Chair
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track
record of innovation and success in developing new oral drug delivery systems. These technologies have been
successfully commercialised in numerous products that continue to be marketed around the world. To learn
more about Mayne Pharma, please visit maynepharma.com.
Mayne Pharma
Group Limited
J.P. Morgan Healthcare Conference
Shawn Patrick O’Brien
January 11, 2024
MYX.ASX
Disclaimer
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited
Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.
Forward looking statements
● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and
contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as
‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express or
implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially
from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under
the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The
factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory
regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major
customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research
collaborations and the Company’s ability to protect its intellectual property.
Other
● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investorrelations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
● DORYX®, FABIOR®, LEXETTE®, RHOFADE® and SORILUX® are trademarks of Mayne Pharma. ABSORICA®, ACCUTANE®, ACZONE®, ANNOVERA®, BIJUVA®,
EPIDUO® FORTE IMVEXXY®, MIRVASO®, NEXTSTELLIS®, ORACEA®, SEYSARA®, SOOLANTRA®, TARGADOX®, VITAMEDMD® and WYNZORA® are trademarks of
third parties.
2
Agenda
FY 2023 Review – Transformed To Optimize For Profitable Growth
Financial Update – Strong Progress Against Our Goals
Dermatology – Access Focus Driving Patient Adherence
– Attracting High Quality Partners
Women’s Health – Portfolio Delivering Solid Financial Results
– Significant Growth Potential
Q&A
3
Mayne Pharma 18 months ago
•US CDMO business – ~21% FY22 revenues, significant profit
contribution, but capital intense
•US RGx business – ~ 36% of FY22 revenues – declining business,
long cash conversion cycle, reduced ability to influence (scale)
•Dermatology business – leveraging spec pharmacy channel to
drive market share, historically volatile results attributable to
channel pricing pressures
•Women’s Health business – reliant on success of single product
(Nextstellis®) with high launch costs
•Large net debt position – unsustainable capital structure
Majority of revenues
under significant
pressure + requiring
large capital outlay
4
FY23 Review – Transforming and Optimizing for Growth
REFOCUSED ON CORE BUSINESS
• Sold US CDMO & US Retail Generics - combined
sale price US$565m
• Expanded US Women’s Health portfolio via
US$140m exclusive license to commercialize 3 onmarket women’s health products
IMPROVED FINANCIAL PERFORMANCE &
RESET CAPITAL STRUCTURE
• Delivered revenue growth across all segments 2H
vs. 1H FY23
• Positive 2H direct contribution and cash flow
• Transformed balance sheet – net cash $176.2m (vs
FY22 net debt $317m)
GREW ALL THREE SEGMENTS
• BPD/Women’s Health – strong revenue growth
following relaunch of NEXTSTELLIS® and 2H
launch of women’s health portfolio expansion;
significant 2H improvement in segment direct
profit contribution
• PPD/Dermatology – delivered significant 2H
turnaround in revenue and gross profit as new
commercial discipline introduced to rebase
business following poor 1H result
• International – revenue, gross profit and direct
contribution growth delivered in 2H; commenced
business improvement program to improve plant
efficiency and secure International CDMO growth
• $46.7m special dividend and commenced onmarket buyback up to 10% of the Company’s
issued capital - increased to up to 15% Nov 2023
AGM
5
Strong start to FY24: YTD through Oct24 - 4 month comparisons Update1
Recurring payments
excluded from
EBITDA2
GROUP in A$ m
Jul-Oct FY23 Mar-Jun FY23 Jul-Oct FY24
Total Net Sales
33.0
97.8
124.8
Total Gross Margin
13.5
47.8
71.7
Total Gross Margin % of Net Sales
41%
49%
57%
Direct OPEX
38.6
43.1
45.3
Indirect OPEX
22.6
23.1
25.7
Underlying EBITDA
-47.3
-17.9
1.0
Earn-out payment liability
-1.6
-1.1
-5.0
Lease payments
-1.1
-1.1
-1.3
Strong total company results
Women’s Health fundamentals improving
•
Net sales of US$30.6M, up 45.3% vs prior 4month
•
All 3 operating segments delivered positive
contribution margin3 for Q1
Net sales US$35.9M, up 55.5% on
prior 4-month
•
NEXTSTELLIS® net selling price (NSP)
restored to prior levels
•
Net sales up 27.5% vs prior 4-month period
•
Gross margin recovery reflecting
core portfolio profitability and new
product launches
•
Gross margin up 50.1% vs prior 4-month
period
•
Initiated a new targeted cost management
program, removing US$10M of costs
Dermatology gaining momentum
•
•
Licensed TXMD products generating robust
returns, maintaining conservative gross-tonet (GTN)
1. All YTD-Oct-FY24 results and comparables unaudited
2. Earn-out liability and lease payment amounts are balance sheet expenditures. The earn-out amount is based on actual sales
3. Contribution margin calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead
6
Dermatology
Dermatology Portfolio Overview
Building market leadership and scale
● Six proprietary brands and 20+ generic dermatologics
● Recent acquisition of RHOFADE®, an FDA-approved topical cream used to treat rosacea (launched 2 Oct 2023)
● Mayne Pharma portfolio can fill 1 in 3 US Dermatology Retail Rx’s1
● Market presence as top 10 US products by revenue - gABSORICA® (isotretinoin) capsules, gEPIDUO® FORTE
(adapalene/benzoyl peroxide) gel and gACZONE® (dapsone) gel
● Building on market position with a strong and profitable pipeline of products to meet broader patient needs
● Differentiated channel strategy through specialty pharmacy growth and online platforms like GoodRx
+20 generic
Dermatology
products
1. IQVIA recent 12-month TRx totals by molecule
8
Dermatology
YTD October FY24 results1
● YTD-FY24 Net Sales +640% vs PCP, +55.5% vs prior 4-month period
FY24 Dermatology
Outlook
● YTD-FY24 Gross Margin +999+% vs PCP, +174% vs prior 4-month period
● Net revenues growing steadily, benefitting from improved GTN and NPLs
(DORYX® MPC 60 mg, AG ORACEA®)
● Unique prescriber patient fulfilment process (disintermediation) is active
● Co-pay monitoring expected to deliver improvements beginning Q2 and
continuing throughout the FY
Derm in US$ m
Jul-Oct FY23 Mar-Jun FY23 Jul-Oct FY24
Total Net Sales
4.9
23.1
35.9
Total Gross Margin
-0.2
5.7
15.6
Total Gross Margin % of Net Sales
-4%
25%
43%
Direct OPEX
7.3
5.4
7.1
Direct Contribution
-7.5
0.2
8.5
Earn-out payment liability
-1.0
0.0
-0.5
• Positive profit and contribution FY24
• Revenue growth via new/recent
product launches (RHOFADE®,
isotretinoin, generic of ORACEA®,
DORYX® MPC 60 mg)
• Transition unique prescriber patient
fulfilment process from pilot to fully
scaled operation
• Enter into accretive business
arrangements and drive commercial
excellence
• 10 product launches expected in US,
October 2023 through June 2024
1. All YTD-FY24 results and comparables unaudited
2. Direct contribution calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead incl med affairs
9
Disintermediation Strategy
Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a
comprehensive, frictionless, transparent, and cost-effective experience
Why Dermatology?
✓ There is great desire for
disintermediation in the industry,
with the Dermatology segment a
logical starting point
✓ Most dermatological conditions are
not permanently cured, resulting in
ongoing demand/continuous refills
✓ Long cycle times for treatment
✓ Conditions are non-acute and
patients are more willing to wait for
shipping and shop online
✓ Insurance coverage is poor and
getting worse
Why Mayne Pharma?
130 territory
representatives
>60% of
prescribing activity
✓ Drug sourcing ability:
• Mayne Pharma portfolio is capable of
filling 1 in 3 US Dermatology Retail Rx(1)
• Access to wholesalers and intermediary
platforms
• Established relationships with Bx & Gx
manufacturers
Manufacturer
✓ Pharmacy network allows for
HCP/Prescriber
consistent product availability,
choice, and pricing:
• Adelaide Apothecary for cash-pay claims,
licensed to operate in 50 states
• 400+ specialty pharmacy locations and
partnerships for reimbursed claims
✓ Extensive provider/customer
Wholesaler
Pharmacy
Patient
coverage:
• 145+ field representatives
• Reach of 50k+ prescribers in targeted
therapeutic areas, covering >60% of
prescribing activity
.
1 IQVIA recent 12-month TRx totals by molecule October 2023
10
Disintermediation Strategy - continued
Mayne Pharma generates gross-to-net savings via disintermediation and utilizes those savings to lower patient out-of-pocket costs
to increase adherence, improve patient and provider satisfaction driving product growth.
Weekly TRx Volume1
Monthly Competitive Market Share1
1. IQVIA Weekly TRx totals, December 2023
11
Women’s Health
Women’s Health Portfolio
Leader in US Women’s Health
● A leading position in strong and growing market with four novel women’s healthcare products1
● Licensing rights acquisition added a complementary portfolio of stable products with long patent lives to the
Company’s flagship women’s health product, NEXTSTELLIS®
● One of the top 2 specialized women’s health companies in the US2
● Strong commercial infrastructure in place with sales team of 94 able to reach target customers
Reproductive Health
1.
2.
Patent protection through 2036 (Nextstellis), 2039 (Annovera), 2034 (Imvexxy), 2032 (Bijuva)
Based on size of US Women’s Health Commercial Operations calling on OB/GYNs.
Menopause Management
Prenatal Vitamins
13
Women’s Health
YTD October FY24 results1
● YTD-FY24 net sales +45.3% for BPD on prior 4-month period
FY24 Women’s Health
Outlook
● Segment performance reflects growth in expansion portfolio as well
as improved performance of NEXTSTELLIS® following access improvements
(co-pay) and new targeting strategy implemented in December 2022
● Continuing to refine NEXTSTELLIS® marketing strategy: reduction of DTC due
to insufficient ROI and removed 6 non-profitable territories
● Direct OPEX increase vs prior year driven by sales force expansion; but have
eliminated US$8 million in segment costs for fiscal year 24
● YTD-FY24 gross margin representative of go-forward profile
BPD in US$ m
Jul-Oct FY23 Mar-Jun FY23 Jul-Oct FY24
Total Net Sales
5.6
21.1
30.6
Total Gross Margin
4.5
18.8
25.2
Total Gross Margin % of Net Sales
81%
89%
82%
Direct OPEX
15.5
21.0
19.8
Direct Contribution
-11.0
-2.2
5.4
Earn-out payment liability
0.0
0.8
-2.7
•
Complete integration of
expansion portfolio with a
focus on growth and
improving net selling prices
•
Deliver Rx growth across
all brands
•
Continued growth of
NEXTSTELLIS®
•
BIJUVA® low strength
launch Q3 FY24
•
ACA law enforcement
impact
1. All YTD-FY24 results and comparables unaudited
2. Direct contribution calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead incl med affairs
14
NEXTSTELLIS® Growth continues
NEXTSTELLIS Product Overview
•
First and only oral contraceptive with a native, selective
estrogen, estetrol (E4). Paired with drospirenone.
•
E4 has selective actions in tissues
•
Supports health of key tissues: uterus, vagina, bone, and
vasculature
•
Neutral impact on liver; not metabolized by CYP450
•
Antagonistic effect on breast tissue – inhibits estradiol
induced cell proliferation
•
Drospirenone: Long half-life (~30 hours), and anti-androgenic
and anti-mineralocorticoid properties
•
Short hormone-free interval (24/4 monophasic regimen)
•
98% efficacy, proven in large, one-year studies with a diverse
population
•
Ages 16-50, racially diverse, up to BMI 35 kg/m2
•
Excellent cycle control, with low rate of breakthrough bleeding,
even at Cycle 1
•
Low rates of side effects often associated with COCs
•
One VTE in EU/Russia Phase 3 study, zero VTE in North America
Phase 3 Study (rate of 3.66 per 10,000 women-years)
•
Patent protection through 2036
Weekly cycles
15
Licensed Portfolio Delivering Financial Results and Significant Growth Potential
Imvexxy® Product Overview
Bijuva® Product Overview
•
•
•
•
•
•
•
•
Bio-identical estradiol, two doses available (4 mcg, 10 mcg)
Lowest vaginal estrogen dose available (4 mcg)
Delivery form: mess-free, easy to use, no applicator, dissolves
quickly
Fast onset of relief (2 weeks)
Systemic estradiol levels stay within normal range for postmenopausal women (not on treatment) with both doses
Affordable co-pay ($15 covered/$45 uncovered or cash)
Patent protection to 2034
Annovera® Product Overview
•
•
•
•
•
•
•
Only FDA-approved combination of bio-identical estradiol and
micronized progesterone
Now available in 2 doses (0.5 mg/100 mg and 1.0 mg/100 mg)
Fast onset: Significant reduction in frequency and severity of VMS in
as early as 4 weeks (both doses)
The only combination product to demonstrate endometrial protection
over one year
In the one-year trial: no clinically meaningful changes in coagulation
factors and lipid parameters. No strokes, heart attacks, or VTE’s
Significant improvements in QOL and sleep
One pill, once a day, one copay ($15 covered/$45 uncovered or cash)
Patent protection to 2032
• High degree (nearly 90%) of patient satisfaction in clinical studies
• Soft and squishy, easy to insert, size of a tampon
• Same ring used for 1-year: no need for monthly refills and no
refrigeration
• Nearly lowest available ethinyl estradiol dose (~13 mcg per day)
and lowest in a ring
• Unique progestin: segesterone acetate – non-androgenic,
derived from progesterone, not from testosterone
• 93% commercially-insured coverage, 87% without restrictions
• $0 copay
• Patent protection to 2039
16
Mayne Pharma Outlook
Mayne Pharma is focused on becoming the market leader in Dermatology and Women’s Health in the US market
Upcoming Launches
Future Portfolio Expansion
✓ Innovative Dermatology
✓ Dermatology
• Soolantra® AG, Jan 2024
• Generic Accutane®, Jan 2024
• Dapsone 5%, 2H 2024
✓ Women’s Health
• Low Dose Bijuva® Jan 2024
Continued Access Focus
✓ GoodRx Prescription Services
• Seamless patient and provider experience while optimizing patient
healthcare benefits
• Establishes a direct relationship with patients and prescribers
• Real time price availability to HCPs and patients
✓ ACA Enforcement for Contraception
✓ Jun ‘23 Executive Order instructing tri-agencies to issue guidance forcing
coverage without cost sharing of all FDA approved products with no
therapeutic equivalent
✓ Dec ‘23 House Oversight Committee report documented abuses and
reinforcing the need for tri-agencies to issue guidance
• Recent partnership with MC2 (WYNZORA®) provides first brand
partnership
• On market asset with patent protection and loyal prescribing base
• Access model expected to improve GTN and access for Mayne
Pharma and our partners
✓ On Market Women’s Health Products
• A number of on market products with appealing profiles
(efficacy/coverage)
• Many marketers have had to pull back / eliminate promotion due to
current market conditions
• Potential to execute partnerships to bring promotion back with
limited downside risk and increase share of voice
✓ Women’s Health Pipeline
• 2024+ will be focused on identifying new assets in development and
executing partnerships to become the market leader in Women’s
Health
17
Strategy for 2024 Growth
Continuing positive momentum into FY24 – solid Q1 momentum continuing into Q2 and beyond
Women’s Health
✓ Deliver positive contribution
margins in all three segments
✓ Return Company to positive
EBITDA and cash generation in
FY24
✓ Optimize cost base with OPEX &
other reductions of > US$10M
✓ Increased share buyback to up to
15%
• Complete integration of
licensed portfolio with a
focus on growth and
improving net selling prices
• Deliver Rx growth across all
branded products
• Continued NEXTSTELLIS®
growth
• BIJUVA® low strength
launch Q3
• ACA law enforcement
impact
Dermatology
International
• New product launches
• Pursue targeted
investments and new
manufacturing revenue
streams
• Transition unique prescriber
patient fulfilment process
from pilot to fully scaled
operation
• Continue to drive specialty
and generic product sales
including NEXTSTELLIS® in
Australia
• Enter into accretive business
arrangements and drive
commercial excellence
• Invest in a targeted manner
in the Salisbury facility to
improve our productivity
and capabilities
• Positive profit and
contribution FY24
18
Q&A
SHAWN PATRICK O’BRIEN
CEO
AARON GRAY
CFO
DANIEL MOORE
EVP, Commercial
You deserve tomorrow.
MYX.ASX
19
Share your feedback
Discover